Engineered Curli Nanofilaments as a Self‐Adjuvanted Antigen Delivery Platform
Proteinaceous nanoparticles constitute efficient antigen delivery systems in vaccine formulations due to their size and repetitive nature that mimic most invading pathogens and promote immune activation. Nonetheless, the coadministration of an adjuvant with subunit nanovaccines is usually required t...
Gespeichert in:
| Veröffentlicht in: | Advanced healthcare materials 2023-08, Vol.12 (21), p.e2300224-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 21 |
| container_start_page | e2300224 |
| container_title | Advanced healthcare materials |
| container_volume | 12 |
| creator | Lamontagne, Félix Arpin, Dominic Côté‐Cyr, Mélanie Khatri, Vinay St‐Louis, Philippe Gauthier, Laurie Archambault, Denis Bourgault, Steve |
| description | Proteinaceous nanoparticles constitute efficient antigen delivery systems in vaccine formulations due to their size and repetitive nature that mimic most invading pathogens and promote immune activation. Nonetheless, the coadministration of an adjuvant with subunit nanovaccines is usually required to induce a robust, long‐lasting, and protective immune response. Herein, the protein Curli‐specific gene A (CsgA), which is known to self‐assemble into nanofilaments contributing to bacterial biofilm, is exploited to engineer an intrinsically immunostimulatory antigen delivery platform. Three repeats of the M2e antigenic sequence from the influenza A virus matrix 2 protein are merged to the N‐terminal domain of engineered CsgA proteins. These chimeric 3M2e‐CsgA spontaneously self‐assemble into antigen‐displaying cross‐β‐sheet nanofilaments that activate the heterodimeric toll‐like receptors 2 and 1. The resulting nanofilaments are avidly internalized by antigen‐presenting cells and stimulate the maturation of dendritic cells. Without the need of any additional adjuvants, both assemblies show robust humoral and cellular immune responses, which translate into complete protection against a lethal experimental infection with the H1N1 influenza virus. Notably, these CsgA‐based nanovaccines induce neither overt systemic inflammation, nor reactogenicity, upon mice inoculation. These results highlight the potential of engineered CsgA nanostructures as self‐adjuvanted, safe, and versatile antigen delivery systems to fight infectious diseases.
The protein Curli‐specific gene A, which is known to self‐assemble into nanofilaments contributing to bacterial biofilm, is engineered to design an intrinsically immunostimulatory antigen delivery nanoplatform for vaccination purpose. These assemblies harboring a conserved influenza A antigen show robust humoral and cellular immune responses, which translate into complete protection against a lethal experimental infection with the H1N1 influenza virus. |
| doi_str_mv | 10.1002/adhm.202300224 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11468023</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2798713379</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4694-f135055afa0ae8707c66e949093ad3e9623d93ac5749135372e46da2b612b8563</originalsourceid><addsrcrecordid>eNqFkctqGzEUhkVJqEPibZdloJts7Og20mhVjHOFXApJ10KeOWPLaDSuNOPgXR-hz5gniYwT97KpEOgIfefnP_oR-kTwmGBMz0y1aMYUU5YulH9AR5QoOqIiVwf7muMBGsa4xGmJnIiCfEQDJjEjRJAj9HDh59YDBKiyaR-cze6Nb2vrTAO-i5lJO3sEV7_8_DWplv3a-C6hE9_ZOfjsHJxdQ9hk35zp6jY0J-iwNi7C8O08Rt8vL56m16Pbh6ub6eR2VHKh-KgmLMd5bmqDDRQSy1IIUFxhxUzFQAnKqlSWueQqoUxS4KIydCYInRW5YMfo60531c8aqMpkNhinV8E2Jmx0a6z--8XbhZ63a00IF0X6sqRw-qYQ2h89xE43NpbgnPHQ9lFTqQpJGJMqoV_-QZdtH3yaT9MiZ0pKzLeWxjuqDG2MAeq9G4L1Ni-9zUvv80oNn_-cYY-_p5MAtQOerYPNf-T05Pz67rf4K8gKoV0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2853977046</pqid></control><display><type>article</type><title>Engineered Curli Nanofilaments as a Self‐Adjuvanted Antigen Delivery Platform</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Lamontagne, Félix ; Arpin, Dominic ; Côté‐Cyr, Mélanie ; Khatri, Vinay ; St‐Louis, Philippe ; Gauthier, Laurie ; Archambault, Denis ; Bourgault, Steve</creator><creatorcontrib>Lamontagne, Félix ; Arpin, Dominic ; Côté‐Cyr, Mélanie ; Khatri, Vinay ; St‐Louis, Philippe ; Gauthier, Laurie ; Archambault, Denis ; Bourgault, Steve</creatorcontrib><description>Proteinaceous nanoparticles constitute efficient antigen delivery systems in vaccine formulations due to their size and repetitive nature that mimic most invading pathogens and promote immune activation. Nonetheless, the coadministration of an adjuvant with subunit nanovaccines is usually required to induce a robust, long‐lasting, and protective immune response. Herein, the protein Curli‐specific gene A (CsgA), which is known to self‐assemble into nanofilaments contributing to bacterial biofilm, is exploited to engineer an intrinsically immunostimulatory antigen delivery platform. Three repeats of the M2e antigenic sequence from the influenza A virus matrix 2 protein are merged to the N‐terminal domain of engineered CsgA proteins. These chimeric 3M2e‐CsgA spontaneously self‐assemble into antigen‐displaying cross‐β‐sheet nanofilaments that activate the heterodimeric toll‐like receptors 2 and 1. The resulting nanofilaments are avidly internalized by antigen‐presenting cells and stimulate the maturation of dendritic cells. Without the need of any additional adjuvants, both assemblies show robust humoral and cellular immune responses, which translate into complete protection against a lethal experimental infection with the H1N1 influenza virus. Notably, these CsgA‐based nanovaccines induce neither overt systemic inflammation, nor reactogenicity, upon mice inoculation. These results highlight the potential of engineered CsgA nanostructures as self‐adjuvanted, safe, and versatile antigen delivery systems to fight infectious diseases.
The protein Curli‐specific gene A, which is known to self‐assemble into nanofilaments contributing to bacterial biofilm, is engineered to design an intrinsically immunostimulatory antigen delivery nanoplatform for vaccination purpose. These assemblies harboring a conserved influenza A antigen show robust humoral and cellular immune responses, which translate into complete protection against a lethal experimental infection with the H1N1 influenza virus.</description><identifier>ISSN: 2192-2640</identifier><identifier>ISSN: 2192-2659</identifier><identifier>EISSN: 2192-2659</identifier><identifier>DOI: 10.1002/adhm.202300224</identifier><identifier>PMID: 37031161</identifier><language>eng</language><publisher>Germany: Wiley Subscription Services, Inc</publisher><subject>Adjuvants ; Adjuvants, Immunologic ; Animals ; Antibodies, Viral ; antigen delivery platforms ; Antigen-presenting cells ; Antigens ; Autoantigens ; Biofilms ; curli‐specific gene A ; Dendritic cells ; Experimental infection ; Humans ; Immune response (cell-mediated) ; Immune response (humoral) ; Immune system ; immunostimulants ; Immunostimulation ; Infectious diseases ; Influenza ; Influenza A ; influenza A virus ; Influenza A Virus, H1N1 Subtype ; Influenza Vaccines ; Influenza, Human ; Inoculation ; Mice ; Mice, Inbred BALB C ; nanofilaments ; Nanoparticles ; nanovaccines ; Proteins ; Robustness ; Viral Matrix Proteins ; Viruses</subject><ispartof>Advanced healthcare materials, 2023-08, Vol.12 (21), p.e2300224-n/a</ispartof><rights>2023 The Authors. Advanced Healthcare Materials published by Wiley‐VCH GmbH</rights><rights>2023 The Authors. Advanced Healthcare Materials published by Wiley-VCH GmbH.</rights><rights>2023. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4694-f135055afa0ae8707c66e949093ad3e9623d93ac5749135372e46da2b612b8563</citedby><cites>FETCH-LOGICAL-c4694-f135055afa0ae8707c66e949093ad3e9623d93ac5749135372e46da2b612b8563</cites><orcidid>0000-0002-5563-8787</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fadhm.202300224$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fadhm.202300224$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37031161$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lamontagne, Félix</creatorcontrib><creatorcontrib>Arpin, Dominic</creatorcontrib><creatorcontrib>Côté‐Cyr, Mélanie</creatorcontrib><creatorcontrib>Khatri, Vinay</creatorcontrib><creatorcontrib>St‐Louis, Philippe</creatorcontrib><creatorcontrib>Gauthier, Laurie</creatorcontrib><creatorcontrib>Archambault, Denis</creatorcontrib><creatorcontrib>Bourgault, Steve</creatorcontrib><title>Engineered Curli Nanofilaments as a Self‐Adjuvanted Antigen Delivery Platform</title><title>Advanced healthcare materials</title><addtitle>Adv Healthc Mater</addtitle><description>Proteinaceous nanoparticles constitute efficient antigen delivery systems in vaccine formulations due to their size and repetitive nature that mimic most invading pathogens and promote immune activation. Nonetheless, the coadministration of an adjuvant with subunit nanovaccines is usually required to induce a robust, long‐lasting, and protective immune response. Herein, the protein Curli‐specific gene A (CsgA), which is known to self‐assemble into nanofilaments contributing to bacterial biofilm, is exploited to engineer an intrinsically immunostimulatory antigen delivery platform. Three repeats of the M2e antigenic sequence from the influenza A virus matrix 2 protein are merged to the N‐terminal domain of engineered CsgA proteins. These chimeric 3M2e‐CsgA spontaneously self‐assemble into antigen‐displaying cross‐β‐sheet nanofilaments that activate the heterodimeric toll‐like receptors 2 and 1. The resulting nanofilaments are avidly internalized by antigen‐presenting cells and stimulate the maturation of dendritic cells. Without the need of any additional adjuvants, both assemblies show robust humoral and cellular immune responses, which translate into complete protection against a lethal experimental infection with the H1N1 influenza virus. Notably, these CsgA‐based nanovaccines induce neither overt systemic inflammation, nor reactogenicity, upon mice inoculation. These results highlight the potential of engineered CsgA nanostructures as self‐adjuvanted, safe, and versatile antigen delivery systems to fight infectious diseases.
The protein Curli‐specific gene A, which is known to self‐assemble into nanofilaments contributing to bacterial biofilm, is engineered to design an intrinsically immunostimulatory antigen delivery nanoplatform for vaccination purpose. These assemblies harboring a conserved influenza A antigen show robust humoral and cellular immune responses, which translate into complete protection against a lethal experimental infection with the H1N1 influenza virus.</description><subject>Adjuvants</subject><subject>Adjuvants, Immunologic</subject><subject>Animals</subject><subject>Antibodies, Viral</subject><subject>antigen delivery platforms</subject><subject>Antigen-presenting cells</subject><subject>Antigens</subject><subject>Autoantigens</subject><subject>Biofilms</subject><subject>curli‐specific gene A</subject><subject>Dendritic cells</subject><subject>Experimental infection</subject><subject>Humans</subject><subject>Immune response (cell-mediated)</subject><subject>Immune response (humoral)</subject><subject>Immune system</subject><subject>immunostimulants</subject><subject>Immunostimulation</subject><subject>Infectious diseases</subject><subject>Influenza</subject><subject>Influenza A</subject><subject>influenza A virus</subject><subject>Influenza A Virus, H1N1 Subtype</subject><subject>Influenza Vaccines</subject><subject>Influenza, Human</subject><subject>Inoculation</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>nanofilaments</subject><subject>Nanoparticles</subject><subject>nanovaccines</subject><subject>Proteins</subject><subject>Robustness</subject><subject>Viral Matrix Proteins</subject><subject>Viruses</subject><issn>2192-2640</issn><issn>2192-2659</issn><issn>2192-2659</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNqFkctqGzEUhkVJqEPibZdloJts7Og20mhVjHOFXApJ10KeOWPLaDSuNOPgXR-hz5gniYwT97KpEOgIfefnP_oR-kTwmGBMz0y1aMYUU5YulH9AR5QoOqIiVwf7muMBGsa4xGmJnIiCfEQDJjEjRJAj9HDh59YDBKiyaR-cze6Nb2vrTAO-i5lJO3sEV7_8_DWplv3a-C6hE9_ZOfjsHJxdQ9hk35zp6jY0J-iwNi7C8O08Rt8vL56m16Pbh6ub6eR2VHKh-KgmLMd5bmqDDRQSy1IIUFxhxUzFQAnKqlSWueQqoUxS4KIydCYInRW5YMfo60531c8aqMpkNhinV8E2Jmx0a6z--8XbhZ63a00IF0X6sqRw-qYQ2h89xE43NpbgnPHQ9lFTqQpJGJMqoV_-QZdtH3yaT9MiZ0pKzLeWxjuqDG2MAeq9G4L1Ni-9zUvv80oNn_-cYY-_p5MAtQOerYPNf-T05Pz67rf4K8gKoV0</recordid><startdate>20230801</startdate><enddate>20230801</enddate><creator>Lamontagne, Félix</creator><creator>Arpin, Dominic</creator><creator>Côté‐Cyr, Mélanie</creator><creator>Khatri, Vinay</creator><creator>St‐Louis, Philippe</creator><creator>Gauthier, Laurie</creator><creator>Archambault, Denis</creator><creator>Bourgault, Steve</creator><general>Wiley Subscription Services, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QF</scope><scope>7QP</scope><scope>7QQ</scope><scope>7SC</scope><scope>7SE</scope><scope>7SP</scope><scope>7SR</scope><scope>7T5</scope><scope>7TA</scope><scope>7TB</scope><scope>7TM</scope><scope>7TO</scope><scope>7U5</scope><scope>8BQ</scope><scope>8FD</scope><scope>F28</scope><scope>FR3</scope><scope>H8D</scope><scope>H8G</scope><scope>H94</scope><scope>JG9</scope><scope>JQ2</scope><scope>K9.</scope><scope>KR7</scope><scope>L7M</scope><scope>L~C</scope><scope>L~D</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-5563-8787</orcidid></search><sort><creationdate>20230801</creationdate><title>Engineered Curli Nanofilaments as a Self‐Adjuvanted Antigen Delivery Platform</title><author>Lamontagne, Félix ; Arpin, Dominic ; Côté‐Cyr, Mélanie ; Khatri, Vinay ; St‐Louis, Philippe ; Gauthier, Laurie ; Archambault, Denis ; Bourgault, Steve</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4694-f135055afa0ae8707c66e949093ad3e9623d93ac5749135372e46da2b612b8563</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adjuvants</topic><topic>Adjuvants, Immunologic</topic><topic>Animals</topic><topic>Antibodies, Viral</topic><topic>antigen delivery platforms</topic><topic>Antigen-presenting cells</topic><topic>Antigens</topic><topic>Autoantigens</topic><topic>Biofilms</topic><topic>curli‐specific gene A</topic><topic>Dendritic cells</topic><topic>Experimental infection</topic><topic>Humans</topic><topic>Immune response (cell-mediated)</topic><topic>Immune response (humoral)</topic><topic>Immune system</topic><topic>immunostimulants</topic><topic>Immunostimulation</topic><topic>Infectious diseases</topic><topic>Influenza</topic><topic>Influenza A</topic><topic>influenza A virus</topic><topic>Influenza A Virus, H1N1 Subtype</topic><topic>Influenza Vaccines</topic><topic>Influenza, Human</topic><topic>Inoculation</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>nanofilaments</topic><topic>Nanoparticles</topic><topic>nanovaccines</topic><topic>Proteins</topic><topic>Robustness</topic><topic>Viral Matrix Proteins</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lamontagne, Félix</creatorcontrib><creatorcontrib>Arpin, Dominic</creatorcontrib><creatorcontrib>Côté‐Cyr, Mélanie</creatorcontrib><creatorcontrib>Khatri, Vinay</creatorcontrib><creatorcontrib>St‐Louis, Philippe</creatorcontrib><creatorcontrib>Gauthier, Laurie</creatorcontrib><creatorcontrib>Archambault, Denis</creatorcontrib><creatorcontrib>Bourgault, Steve</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Online Library Free Content</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Aluminium Industry Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Ceramic Abstracts</collection><collection>Computer and Information Systems Abstracts</collection><collection>Corrosion Abstracts</collection><collection>Electronics & Communications Abstracts</collection><collection>Engineered Materials Abstracts</collection><collection>Immunology Abstracts</collection><collection>Materials Business File</collection><collection>Mechanical & Transportation Engineering Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Solid State and Superconductivity Abstracts</collection><collection>METADEX</collection><collection>Technology Research Database</collection><collection>ANTE: Abstracts in New Technology & Engineering</collection><collection>Engineering Research Database</collection><collection>Aerospace Database</collection><collection>Copper Technical Reference Library</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Materials Research Database</collection><collection>ProQuest Computer Science Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Civil Engineering Abstracts</collection><collection>Advanced Technologies Database with Aerospace</collection><collection>Computer and Information Systems Abstracts Academic</collection><collection>Computer and Information Systems Abstracts Professional</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Advanced healthcare materials</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lamontagne, Félix</au><au>Arpin, Dominic</au><au>Côté‐Cyr, Mélanie</au><au>Khatri, Vinay</au><au>St‐Louis, Philippe</au><au>Gauthier, Laurie</au><au>Archambault, Denis</au><au>Bourgault, Steve</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Engineered Curli Nanofilaments as a Self‐Adjuvanted Antigen Delivery Platform</atitle><jtitle>Advanced healthcare materials</jtitle><addtitle>Adv Healthc Mater</addtitle><date>2023-08-01</date><risdate>2023</risdate><volume>12</volume><issue>21</issue><spage>e2300224</spage><epage>n/a</epage><pages>e2300224-n/a</pages><issn>2192-2640</issn><issn>2192-2659</issn><eissn>2192-2659</eissn><abstract>Proteinaceous nanoparticles constitute efficient antigen delivery systems in vaccine formulations due to their size and repetitive nature that mimic most invading pathogens and promote immune activation. Nonetheless, the coadministration of an adjuvant with subunit nanovaccines is usually required to induce a robust, long‐lasting, and protective immune response. Herein, the protein Curli‐specific gene A (CsgA), which is known to self‐assemble into nanofilaments contributing to bacterial biofilm, is exploited to engineer an intrinsically immunostimulatory antigen delivery platform. Three repeats of the M2e antigenic sequence from the influenza A virus matrix 2 protein are merged to the N‐terminal domain of engineered CsgA proteins. These chimeric 3M2e‐CsgA spontaneously self‐assemble into antigen‐displaying cross‐β‐sheet nanofilaments that activate the heterodimeric toll‐like receptors 2 and 1. The resulting nanofilaments are avidly internalized by antigen‐presenting cells and stimulate the maturation of dendritic cells. Without the need of any additional adjuvants, both assemblies show robust humoral and cellular immune responses, which translate into complete protection against a lethal experimental infection with the H1N1 influenza virus. Notably, these CsgA‐based nanovaccines induce neither overt systemic inflammation, nor reactogenicity, upon mice inoculation. These results highlight the potential of engineered CsgA nanostructures as self‐adjuvanted, safe, and versatile antigen delivery systems to fight infectious diseases.
The protein Curli‐specific gene A, which is known to self‐assemble into nanofilaments contributing to bacterial biofilm, is engineered to design an intrinsically immunostimulatory antigen delivery nanoplatform for vaccination purpose. These assemblies harboring a conserved influenza A antigen show robust humoral and cellular immune responses, which translate into complete protection against a lethal experimental infection with the H1N1 influenza virus.</abstract><cop>Germany</cop><pub>Wiley Subscription Services, Inc</pub><pmid>37031161</pmid><doi>10.1002/adhm.202300224</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-5563-8787</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2192-2640 |
| ispartof | Advanced healthcare materials, 2023-08, Vol.12 (21), p.e2300224-n/a |
| issn | 2192-2640 2192-2659 2192-2659 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11468023 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | Adjuvants Adjuvants, Immunologic Animals Antibodies, Viral antigen delivery platforms Antigen-presenting cells Antigens Autoantigens Biofilms curli‐specific gene A Dendritic cells Experimental infection Humans Immune response (cell-mediated) Immune response (humoral) Immune system immunostimulants Immunostimulation Infectious diseases Influenza Influenza A influenza A virus Influenza A Virus, H1N1 Subtype Influenza Vaccines Influenza, Human Inoculation Mice Mice, Inbred BALB C nanofilaments Nanoparticles nanovaccines Proteins Robustness Viral Matrix Proteins Viruses |
| title | Engineered Curli Nanofilaments as a Self‐Adjuvanted Antigen Delivery Platform |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T04%3A06%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Engineered%20Curli%20Nanofilaments%20as%20a%20Self%E2%80%90Adjuvanted%20Antigen%20Delivery%20Platform&rft.jtitle=Advanced%20healthcare%20materials&rft.au=Lamontagne,%20F%C3%A9lix&rft.date=2023-08-01&rft.volume=12&rft.issue=21&rft.spage=e2300224&rft.epage=n/a&rft.pages=e2300224-n/a&rft.issn=2192-2640&rft.eissn=2192-2659&rft_id=info:doi/10.1002/adhm.202300224&rft_dat=%3Cproquest_pubme%3E2798713379%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2853977046&rft_id=info:pmid/37031161&rfr_iscdi=true |